Study guide
8.2 Practice Management
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
8.2 Practice Management
Key Takeaways Explain This Topic AI
Pharmacy gross margin equals selling price minus cost of goods sold, and net profit subtracts operating expenses from gross margin.
NADAC (National Average Drug Acquisition Cost) is a CMS survey-based retail acquisition cost benchmark, distinct from AWP and WAC list prices.
Star Ratings drive Part D quality bonus payments; key pharmacist-influenced measures include medication adherence (PDC >80%), statin use in diabetes, and high-risk medication use in the elderly.
The 2023 CMS final rule requires Part D DIR fees to be reflected at point-of-sale starting in 2024, narrowing but not eliminating reimbursement unpredictability.
SWOT analysis frames strategic decisions across Strengths, Weaknesses, Opportunities, and Threats, supporting business plan development and service expansion.
Last updated: July 2026
Practice Management
Quick Answer: Pharmacy practice management integrates financial stewardship, strategic planning, personnel oversight, and operational workflow to deliver safe, profitable services. Pharmacists must understand reimbursement acronyms (AWP, WAC, MAC, NADAC), budget types, Star Ratings, and the impact of DIR fees on net margin.
Financial Management and Budgeting
Pharmacy revenue streams include dispensing fees, clinical service fees (immunizations, MTM, point-of-care testing), third-party reimbursement, and direct cash sales. The gross margin equals selling price minus cost of goods sold; net profit subtracts operating expenses (rent, payroll, utilities, software) from gross margin. Tracking gross profit per prescription is essential because narrow per-prescription margins must be offset by prescription volume.
Reimbursement Benchmarks
Payers use several benchmarks to calculate reimbursement.
- Acronym Meaning Notes
- AWP Average Wholesale Price Published list price; ~20% above WAC
- WAC Wholesale Acquisition Cost Manufacturer's list price to wholesalers
- MAC Maximum Allowable Cost Payer-set ceiling for generics
- NADAC National Average Drug Acquisition Cost CMS survey-based retail cost benchmark
- ASP Average Sales Price Used for Part B physician-administered drugs
- AAC Actual Acquisition Cost Medicaid cost-based reimbursement
A typical reimbursement formula is Reimbursement = (MAC × ingredient cost) + dispensing fee . The dispensing fee is meant to cover overhead, but it rarely reflects true dispensing cost, which national cost studies place near $10 to $12 per prescription while Medicaid dispensing fees often sit below $3. Understanding which benchmark a contract uses is critical: a contract priced off AWP inflates total reimbursement but is often paired with larger DIR fees, while a NADAC-based contract better reflects acquisition cost and is harder to discount retroactively.
Third-Party Contract Management
Pharmacies contracted with Medicare Part D, Medicaid managed care, and commercial PBMs must monitor remittance advices for shortfalls, audit payer remits against expected reimbursement, and reconcile copay collection against the insurer's coordination-of-benefits rules. Prompt-pay laws in most states require payers to pay clean claims within a set number of days (often 14) or pay interest. Pharmacies that fail to audit payer remits routinely absorb silent rate reductions and clawbacks that erode an already narrow margin.
Budgeting
Operating budget — recurring revenue and expenses for the year (payroll, inventory, utilities).
Capital budget — long-lived purchases (automation, refrigerators, remodels), evaluated using payback period or net present value.
Cash flow analysis — tracks timing of receipts and disbursements; critical because third-party payments lag dispensing by 30 to 60 days.
Business and Strategic Planning
A business plan articulates mission, market analysis, service offerings, financial projections, and operational plan. SWOT analysis — Strengths, Weaknesses, Opportunities, Threats — frames strategic decisions. A community pharmacy weighing MTM expansion might list: Strength — trusted patient relationships; Weakness — limited staff capacity; Opportunity — payer MTM contracts; Threat — mail-order competition. Market analysis examines competitors, demographics, payer mix, and unmet needs (e.g., no immunization provider within 5 miles).
Personnel Management
Effective staffing models balance volume, complexity, and regulatory scope. The pharmacist-to-technician ratio varies by state; many states allow up to 1:4 or higher with technician product verification (TPV). Scheduling must cover peaks (lunch, after-work rushes) while controlling overtime. Performance evaluation uses objective metrics — prescriptions per hour, error rate, MTM completions — paired with behavioral feedback. The Pharmacy Quality Commitment and ISMP guidelines emphasize a non-punitive safety culture where staff report near-misses without fear.
Pharmacy Operations and Workflow
Workflow design — drop-off, data entry, fill, product verification, pick-up — should minimize hand-offs and interruptions, both major causes of error. Inventory management balances availability against carrying cost. E-prescribing improves legibility and reduces transcription errors but introduces new error modes (wrong-direction dropdowns). Pharmacy information systems (PIS) integrate dispensing, drug utilization review (DUR) alerts, and reporting. Robotics and automation (counting robots, carousels, IV workflow software) reduce selection errors and free pharmacists for clinical work.
Service Expansion
Clinical services broaden revenue beyond dispensing:
Immunizations — pharmacy-based influenza, COVID-19, shingles, pneumococcal, and travel vaccines.
MTM and CMR — billable comprehensive medication reviews under Medicare Part D.
Disease state management — pharmacist-run clinics for diabetes, hypertension, anticoagulation, and asthma.
Point-of-care testing — A1c, lipid panels, strep, influenza, COVID-19, and HIV testing.
Quality Metrics
Payer and accreditation quality measures drive reimbursement.
Star Ratings (CMS Part D) — measures like medication adherence (PDC >80%), statin use in diabetes, ACE/ARB use in diabetes, and high-risk medication use in the elderly. Plans earning 4 or more stars receive quality bonus payments that flow to pharmacies.
HEDIS — Healthcare Effectiveness Data and Information Set, used by NCQA-accredited health plans.
PQA measures — Pharmacy Quality Alliance endorses measures such as Proportion of Days Covered (PDC) for diabetes, hypertension, and statins.
Reimbursement Challenges: DIR Fees
Pharmacy Direct and Indirect Remuneration (DIR) fees are post-adjudication clawbacks by pharmacy benefit managers (PBMs), applied retroactively for missing quality targets or simply as a contracted amount. They erode already-thin margins and create unpredictable cash flow. The 2023 CMS Part D rule requires DIR to be reflected at point-of-sale starting in 2024, narrowing but not eliminating the challenge. Pharmacists should monitor remittance advices, reconcile expected versus received reimbursement, and engage actively in PBM contract negotiations.